Search research articles
Contact Us
Filters
Showing results (501-510 of 532) with videos related to
Page
of 54
Sort By:
Journal of Cardiovascular Computed Tomography
|
March 3, 2023
Appropriateness of cardiovascular computed tomography and magnetic resonance imaging in patients with conotruncal defects
Sarah S Pickard, Aimee K Armstrong, Sowmya Balasubramanian, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 2, 2025
The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response
Ruby Pandher, Chengyuan Xue, Laura D Gamble, et al.
Oncotarget
|
October 21, 2016
The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs
Pei Y Liu, Nicholas Sokolowski, Su T Guo, et al.
Haematologica
|
September 23, 2017
High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment
Susan L Heatley, Teresa Sadras, Chung H Kok, et al.
Oncogene
|
March 4, 2021
A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma
Belamy B Cheung, Ane Kleynhans, Rituparna Mittra, et al.
Science Translational Medicine
|
May 17, 2023
Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia
Ernest Moles, Christopher B Howard, Pie Huda, et al.
International Journal of Cancer
|
November 8, 2022
Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma
Janith A Seneviratne, Daniel R Carter, Rituparna Mittra, et al.
Nature Communications
|
July 27, 2019
JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma
Matthew Wong, Yuting Sun, Zhichao Xi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2025
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancer
Surendra Nayak, John D Norris, Massimo Ammirante, et al.
Leukemia
|
February 15, 2013
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation
G M Marshall, L Dalla Pozza, R Sutton, et al.
Page
of 54
Search research articles
Search
Showing results (501-510 of 532) with videos related to
Sort By:
Page
of 54
Journal of Cardiovascular Computed Tomography
|
March 3, 2023
Appropriateness of cardiovascular computed tomography and magnetic resonance imaging in patients with conotruncal defects
Sarah S Pickard, Aimee K Armstrong, Sowmya Balasubramanian, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 2, 2025
The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response
Ruby Pandher, Chengyuan Xue, Laura D Gamble, et al.
Oncotarget
|
October 21, 2016
The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs
Pei Y Liu, Nicholas Sokolowski, Su T Guo, et al.
Haematologica
|
September 23, 2017
High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment
Susan L Heatley, Teresa Sadras, Chung H Kok, et al.
Oncogene
|
March 4, 2021
A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma
Belamy B Cheung, Ane Kleynhans, Rituparna Mittra, et al.
Science Translational Medicine
|
May 17, 2023
Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia
Ernest Moles, Christopher B Howard, Pie Huda, et al.
International Journal of Cancer
|
November 8, 2022
Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma
Janith A Seneviratne, Daniel R Carter, Rituparna Mittra, et al.
Nature Communications
|
July 27, 2019
JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma
Matthew Wong, Yuting Sun, Zhichao Xi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2025
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancer
Surendra Nayak, John D Norris, Massimo Ammirante, et al.
Leukemia
|
February 15, 2013
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation
G M Marshall, L Dalla Pozza, R Sutton, et al.
Page
of 54